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Reply
We thank Drs. Musette et al for their interesting comments on
our study ‘‘First comparative delineation of the T-cell receptor
repertoire in primary and multiple subsequent/coexisting
metastatic melanoma sites’’ (Strohal et al, 1998) and offer the
following reply.
The value of phenotypic TCR analyses for a reliable
monitoring of tumor-triggered host responses in situ is directly
dependant on their capacity to follow TCR moieties expressed
by potentially tumor-reactive lymphocytes. Based on the
observation that antigen-driven T cell responses are able to
induce the generation of numerically expanded and clonally
restricted TCR specificities (Hedrick and Eidelman, 1993; Weiss,
1993), there exist two different strategies for the identification
of those BV specificities that are likely to comprise functionally
relevant TCR clonotypes. The vast majority of investigators,
including ourselves, are using a semiquantitative PCR and
Southern blot technique to identify certain BV specificities on
the basis of their numerical predominance (TCRBV melanoma/
mean 1 2SD TCR-BV PBL ù 1) within the TCR repertoire
of a given melanoma specimen (reviewed in Sensi and Parmiani,
1995), and are then analysing the clonal status of all the
dominating BV-associated TCR transcripts by producing and
screening BV-BC fragment libraries with a final CDR3 region-
sequencing procedure of library-related TCR cDNA clones. In
contrast, Musette et al consider the parameter of CDR3 region
clonality as a major decision criterion for the selection of BV
families to be further analyzed, and have developed a detection
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system, the immunoscope technique, which initially defines the
overall CDR3 region length polymorphism of each BV specificity
expressed by TIL of the respective melanoma specimen (Pannetier
et al, 1998). Musette et al favor this experimental approach on
the basis of phenotypic TCR data (Puisieux et al, 1994), showing
that the expansion of a clonal T cell population does not always
result in an overall increased expression of the related BV gene
segment. Consequently, they are suggesting that semiquantitative
procedures do not generate an accurate picture of antigen-driven
immune responses. Due to ample evidence from their own
previous data and different functional studies from the literature
indicating that both techniques are leading to, at least, equally
reliable results, we cannot accept the authors’ objection. In
detail, a phenotypic and functional study by Bachelez et al
(1998) using both the semiquantitative PCR/Southern blot
technology and the immunoscope technique clearly demonstrated
that those BV families presenting with oligoclonal or clonal
peaks (patient A/SIL1: BV8 and BV16, patient C/SIL1: BV8)
were also numerically predominating the TCRBV repertoire in
the respective skin lesions, and, with regard to BV8-expressing,
CD81 lesion-derived cell lines, also harbored functional TCR
clonotypes. In addition, even in the work by Puisieux et al
(1994) that has been cited by the authors to support their
statement, the only BV specificity that comprises TCR clonotypes
shared by all melanoma specimens and PBL (patient BON/BV3)
is the one which, on a semiquantative basis, is part of the small
group of BV families dominating the TCR repertoire in the
specimens tested. Moreover, various mouse and human studies
targeting the important question, whether the clonal expansion
of certain tumor-reactive TCR transcripts is leading to a
numerical expression peak of the overall related BV family,
showed that, indeed, those TCR clonotypes that carried the in
situ predominating BV specificities also displayed specific HLA
class 1-restricted lytic activity against autologous melanoma cells
in vitro (Ferradini et al, 1993; Mackensen et al, 1994; Kurt et al,
1995; Sensi et al, 1997). Thus, it is very likely that functionally
relevant T cell mediated responses in situ are characterized by
clonal restriction as well as numerical expansion. Following this
rationale, we actually did not intend to establish and perform a
highly stringent PCR technology that might lead to the
identification of numerous different clonal TCR transcripts just
representing minute portions of tumor-related TIL. Nevertheless,
our screening procedure of BV-BC cDNA libraries did provide
enough sensitivity to demonstrate that certain TCR clonotypes
shared by multiple tumor deposits often presented with site-
specific quantitative differences of expression, in that they
undergo a major expansion in one of the respective sites only.
In fact, these findings are compatible with the conclusion of
Musette et al that expansion of the same clones at distinct sites
is a clue to the in vivo efficiency of T cells in malignant diseases.
We also have difficulties in accepting the authors’ concern
regarding major discrepancies between our data and studies by
Puisieux et al (1994) and Musette et al (1999) characterizing the
diversity of TCR-β-chains in multiple melanoma specimens and
halo nevi, respectively. Identifying T cell clones that are
infiltrating all halo nevi and melanoma deposits of a given
patient, these authors conclude that the results of our study lacking
such identical CDR3 region sequences at all tumor sites might not
create an authentic picture of T cell mediated host responses in
the patients investigated. The authors, however, are referring to
studies that were analysing different material as compared with our
work. While Drs. Puisieux and Musette delineated skin-associated
TCR configurations in subcutaneous metastases (together with one
affected lymph node and PBL used for control purposes) as well as
nevi, we were dealing with multiple metastatic specimens from
different nonskin-related organ sites. In this context we would like
to emphasize previous reports from our laboratory showing that (i)
TIL within cutaneous lesions often express the cutaneous leukocyte
antigen (CLA), whereas lymphocytes infiltrating extracutaneous
tumor deposits do not display this skin-homing receptor (Strohal
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et al, 1994a), and that (ii) TIL within 24 different skin-related
benign and malignant melanocytic lesions preferentially use three
identical AV families also present in the TCR repertoire of normal
unaffected skin (Strohal et al, 1994b). These observations, which
are in keeping with Musette’s CLA expression data in halo nevi
and TCR clonotype analyses by Drs. Puisieux and Musette, suggest
that lymphocytes infiltrating cutaneous melanoma belong to a
T cell subset functionally associated with the skin. Hence, to evaluate
the concept of distinct organ-related immunologic compartments
directly influencing the quality and quantity of T cell mediated
antimelanoma host responses, the study herein discussed was
successfully intending to define TCR-AV/BV usage, CDR3 region
diversity, and melanoma-associated antigen expression patterns in
skin-related and noncutaneous coexisting/subsequent metastatic
melanoma sites. Notwithstanding the technology being used to
analyse the TCR repertoire in TIL of different immunologic
compartments, we wish to emphasize again that functional in vitro
assays are needed to learn more about the actual target profiles of
these locally expanded TCR clonotypes.
Robert Strohal, Georg Stingl
Division of Immunology, Allergy and Infectious Diseases,
Department of Dermatology, University of Vienna Medical
School, Vienna, Austria
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Human Herpesvirus 7 and Pityriasis Rosea
To the Editor:
Pityriasis rosea (PR) is a common, acute, self-limited papulosquam-
ous disorder that usually lasts for 4–7 wk. Several clinical features
have suggested a viral cause, including occasional association of
prodromal symptoms, clustering in families or communities, and
an increased incidence in patients with decreased immunity, such
as in pregnant or bone-marrow transplantation patients. It has been
reported that human herpesvirus 7 (HHV7) was present in cell-
free plasma, peripheral blood mononuclear cells, and lesional skin
from all 12 PR patients examined (Drago et al, 1997a, b); however,
their conclusion has yet to be verified by other studies.1 We
investigated the presence of HHV7 sequences and antibodies against
HHV7 in 81 plasma samples from 36 patients with PR.
The plasma samples were suspended in K-buffer and DNA was
extracted with phenol and chloroform (Drago et al, 1997a). All
examinations were performed under code. We used previously
described primers (Drago et al, 1997a, b) to amplify a 264-bp
HHV7-DNA that was located between base pairs 83998 and 84261
of the published sequences (Nicholas, 1996). Of 36 patients, 16
Manuscript received April 14, 1999; accepted for publication April
30, 1999.
Reprint requests to: Dr. Takahiro Watanabe, Department of Dermato-
logy, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-
ku, Tokyo, 113–0033, Japan.
1Kempf W, Adams V, Kleinhans M, Burg G, Panizzon RG, Campadelli-
Fiume G, Nestle F: Human herpesvirus and pityriasis rosea. J Invest Dermatol
110:666, 1998 (abstr)
T: Analysis of the T cell receptor variability in tumor-infiltrating lymphocytes
from a human regressing melanoma. J Clin Invest 91:1183–1190, 1993
Hedrick SM, Eidelman FJ. T lymphocyte antigen receptors. In: Paul WE (eds).
Fundamental Immunology. Raven Press, New York, 1993, pp. 383–420
Kurt RA, Park JA, Panelli MC, Schluter SF, Marchalonis JJ, Carolus B, Akporiaye
ET: T lymphocytes infiltrating sites of tumor rejection and progression
display identical Vβ usage but different cytotoxic activities. J Immunol 154:
3969–3974, 1995
Mackensen A, Carcelain G, Viel S, et al: Direct evidence to support the
immunosurveillance concept in a human regressing melanoma. J Clin Invest
93:1397–1402, 1994
Musette P, Bachelez H, Flageul B, Delarbre C, Kourilsky P, Dubertret L,
Gachelin G: Immune-mediated destruction of melanocytes in halo nevi is
associated with the local expansion of a limited number of T cell clones.
J Immunol 162:1789–1794, 1999
Pannetier C, Levraud JP, Lim A, Even J, Kourilsky P. The Immunoscope
approach for the analysis of T cell repertoires. In: Oksenberg JR (eds). The
Antigen T Cell Receptor: Selected Protocols and Applications. Chapman & Hall,
New York, 1998, pp. 287–325
Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P: Oligoclonality
of tumor-infiltrating lymphocytes from human melanomas. J Immunol 153:
2807–2818, 1994
Sensi M, Garina C, Maccalli C, et al: Clonal expansion of T lymphocytes in
human melanoma metastases after treatment with a hapten-modified
autologous vaccine. J Clin Invest 99:707–717, 1997
Sensi M, Parmiani G: Analysis of TCR usage in human tumors: a new tool for
assessing tumor-specific immune responses. Immunol Today 16:588–595, 1995
Strohal R, Marberger K, Pehamberger H, Stingl G: Immunohistological analysis
of anti-melanoma host responses. Arch Derm Res 287:28–35, 1994a
Strohal R, Paucz L, Pehamberger H, Stingl G: T-cell receptor repertoire of
lymphocytes infiltrating cutaneous melanoma is predominated by Vα
specificities present in T-cells of normal human skin. Cancer Res 54:4734–
4739, 1994b
Strohal R, Brna C, Mossbacher U, Fischer G, Pehamberger H, Stingl G: First
comparative delineation of the T-cell receptor repertoire in primary and
multiple subsequent/coexisting metastatic melanoma sites. J Invest Dermatol
111:1085–1091, 1998
Weiss A. T lymphocyte activation. In: Paul WE (eds). Fundamental Immunology.
Raven Press, New York, 1993, pp. 467–504
were positive at one time point and one (No. 11) was positive at
two time points (Fig 1). The direct sequencing of the polymerase
chain reaction products revealed that all but one plasma sample
had exactly the same sequence as in the database, and that the
remaining sample (No. 12) had a nucleic acid alteration: G at base
pair 84142 was changed to C. The specificity of polymerase chain
reaction was demonstrated by the lack of HHV7 sequences in the
31 plasma samples from age- and gender-matched healthy controls.
The same plasma samples were further investigated for the
prevalence of antibodies to HHV7. An indirect immunofluorescent
assay was carried out according to previously described procedures
(Wyatt et al, 1991) with some modifications. SupT1 cells infected
with HHV7 (Sato strain, provided by SRL, Tokyo, Japan) were
fixed and then incubated with 2-fold serially diluted serum. The
titer was defined as the reciprocal of the final dilution that gave a
positive response. All cases, including 31 healthy controls, were
negative (,10) for IgM. A significant increase (.4) of IgG was
detected in one PR patient (No. 10); however, neither a significant
increase nor a decrease in titers of IgG in the other PR patients
was observed.
We cannot fully confirm a direct causal relationship between
PR and HHV7 because the viral sequences were transiently found
in about half of the patients and the result of IFA did not suggest
the reactivation of HHV7 in PR. An insufficient number of viruses
may be reactivated during the period of PR to provoke a significant
increase of antibodies against HHV7, or the causative factor of PR
may be heterogeneous and unattributable to a single infectious
agent. The virus was found up to 7 wk after the first consultation,
the same amount of time that the symptoms of PR usually persist,
although this might have reflected decreased immunity of the host.
